1,834 Shares in Stryker Co. (NYSE:SYK) Bought by Fox Run Management L.L.C.

Fox Run Management L.L.C. purchased a new stake in Stryker Co. (NYSE:SYK) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,834 shares of the medical technology company’s stock, valued at approximately $660,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Meridian Wealth Management LLC acquired a new position in Stryker during the 3rd quarter worth approximately $665,000. Swedbank AB lifted its position in shares of Stryker by 10.9% during the 3rd quarter. Swedbank AB now owns 51,070 shares of the medical technology company’s stock worth $18,450,000 after purchasing an additional 5,032 shares during the last quarter. Summit Trail Advisors LLC grew its stake in shares of Stryker by 8.7% during the third quarter. Summit Trail Advisors LLC now owns 5,494 shares of the medical technology company’s stock worth $1,989,000 after purchasing an additional 441 shares in the last quarter. Daiwa Securities Group Inc. increased its holdings in Stryker by 12.3% in the third quarter. Daiwa Securities Group Inc. now owns 49,003 shares of the medical technology company’s stock valued at $17,703,000 after buying an additional 5,368 shares during the last quarter. Finally, Davis R M Inc. raised its stake in Stryker by 2.7% in the third quarter. Davis R M Inc. now owns 123,960 shares of the medical technology company’s stock valued at $44,782,000 after buying an additional 3,279 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity

In other news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Price Performance

Shares of NYSE SYK opened at $374.43 on Tuesday. The stock has a fifty day moving average price of $384.55 and a 200 day moving average price of $374.24. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a market cap of $142.87 billion, a PE ratio of 48.25, a P/E/G ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the business earned $3.46 EPS. Sell-side analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is 43.30%.

Analyst Upgrades and Downgrades

SYK has been the subject of several analyst reports. Stifel Nicolaus upped their price objective on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Canaccord Genuity Group increased their price target on shares of Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a report on Thursday, March 6th. The Goldman Sachs Group set a $422.00 target price on shares of Stryker in a report on Tuesday, March 4th. Finally, Wells Fargo & Company lifted their price target on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.